Flexion Therapeutics issues two new patents to strengthen intellectual property protection for Zilretta

|About: Flexion Therapeutics, Inc. (FLXN)|By:, SA News Editor

Flexion Therapeutics (NASDAQ:FLXN) announces the U.S. Patent and Trademark Office has issued two new patents covering the company’s lead investigational product candidate Zilretta (FX006).

The first patent includes the treatment of a variety of indications associated with pain and inflammation. The second covers methods of manufacturing injectable extended-release microparticles that combine triamcinolone acetonide and PLGA.

Zilretta’s composition of matter, method of use and method of manufacturing patents provide protection into 2031.

Zilretta is being investigated as the first intra-articular, extended-release treatment for patients with osteoarthritis (OA)-related knee pain.